Related references
Note: Only part of the references are listed.HuR Regulates β-Tubulin Isotype Expression in Ovarian Cancer
Giuseppina Raspaglio et al.
CANCER RESEARCH (2010)
βIII-Tubulin Is a Multifunctional Protein Involved in Drug Sensitivity and Tumorigenesis in Non-Small Cell Lung Cancer
Joshua A. McCarroll et al.
CANCER RESEARCH (2010)
Cardiac Progenitor Cell Cycling Stimulated by Pim-1 Kinase
Christopher T. Cottage et al.
CIRCULATION RESEARCH (2010)
Hypoxia-Mediated Up-Regulation of Pim-1 Contributes to Solid Tumor Formation
Jian Chen et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer
Robert S. Kerbel
BREAST (2009)
Paclitaxel Directly Binds to Bcl-2 and Functionally Mimics Activity of Nur77
Cristiano Ferlini et al.
CANCER RESEARCH (2009)
Src kinases as therapeutic targets for cancer
Lori C. Kim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Molecular Mechanisms of Patupilone Resistance
Simona Mozzetti et al.
CANCER RESEARCH (2008)
Class III β-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel
Carlos M. Galmarini et al.
CLINICAL CANCER RESEARCH (2008)
Hypoxia induces class III beta-tubulin gene expression by HIF-1α binding to its 3' flanking region
Giuseppina Raspaglio et al.
GENE (2008)
Reviews in molecular biology and biotechnology: Transmembrane signaling by G protein-coupled receptors
Louis M. Luttrell
MOLECULAR BIOTECHNOLOGY (2008)
From plasma membrane to cytoskeleton: a novel function for semaphorin 6A
Silvia Prislei et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents?
Pascal Seve et al.
LANCET ONCOLOGY (2008)
Class III β-tubulin mediates sensitivity to chemotherapeutic drugs in non-small cell lung cancer
Pei Pei Gan et al.
CANCER RESEARCH (2007)
Class III β-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer:: Analysis of NCIC JBR.10
Pascal Seve et al.
CLINICAL CANCER RESEARCH (2007)
Survival benefits with diverse chemotherapy regimens for ovarian cancer: Meta-analysis of multiple treatments
Maria Kyrgiou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
Class III β-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients
G Ferrandina et al.
CLINICAL CANCER RESEARCH (2006)
The dynamic instability of microtubules is required for aggresome formation in oligodendroglial cells after proteolytic stress
Nina G. Bauer et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2006)
GBP1 overexpression is associated with a paclitaxel resistance phenotype
ZF Duan et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
The seco-taxane IDN5390 is able to target class III β-tubulin and to overcome paclitaxel resistance
C Ferlini et al.
CANCER RESEARCH (2005)
Share Paper
